Monthly Communication Report

Corporation:	Amgen Canada Inc.
Associated registration:	952471-15332-36
Communication date:	2025-10-21
Posted date:	2025-10-27

Designated Public Office Holders who participated in the communication:	Maggie Chi, Member of Parliament for Don Valley North House of Commons
List of Details Subject matter Detail Economic Development, Science and Technology Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy. Health, International Trade, Science and Technology Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors. Health Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products. Health, Science and Technology Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
Responsible Officer who filed this communication report:	Ugur Gunaydin
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.